Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Other financing activities (2018 - 2026)

Heron Therapeutics filings provide 9 years of Other financing activities readings, the most recent being -$51000.0 for Q1 2026.

  • On a quarterly basis, Other financing activities fell 179.69% to -$51000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.3 million, a 459.27% decrease, with the full-year FY2025 number at $160000.0, down 47.19% from a year prior.
  • Other financing activities hit -$51000.0 in Q1 2026 for Heron Therapeutics, up from -$1.4 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $318000.0 in Q2 2024 to a low of -$1.4 million in Q4 2025.
  • Median Other financing activities over the past 5 years was -$51000.0 (2025), compared with a mean of -$196764.7.
  • The widest YoY moves for Other financing activities: up 481.82% in 2025, down 3415.38% in 2025.
  • Heron Therapeutics' Other financing activities stood at -$215000.0 in 2022, then skyrocketed by 99.07% to -$2000.0 in 2023, then plummeted by 1850.0% to -$39000.0 in 2024, then crashed by 3415.38% to -$1.4 million in 2025, then soared by 96.28% to -$51000.0 in 2026.
  • The last three reported values for Other financing activities were -$51000.0 (Q1 2026), -$1.4 million (Q4 2025), and -$51000.0 (Q3 2025) per Business Quant data.